Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | AGIO |
---|---|---|
09:32 ET | 6991 | 44.115 |
09:34 ET | 1317 | 43.865 |
09:36 ET | 1749 | 43.805 |
09:38 ET | 100 | 44 |
09:39 ET | 1740 | 44.01 |
09:41 ET | 300 | 43.98 |
09:43 ET | 100 | 43.96 |
09:45 ET | 1346 | 44.03 |
09:48 ET | 4539 | 43.5696 |
09:50 ET | 3500 | 43.69 |
09:52 ET | 3956 | 43.505 |
09:54 ET | 600 | 43.55 |
09:56 ET | 920 | 43.5989 |
09:57 ET | 800 | 43.68 |
09:59 ET | 1301 | 43.81 |
10:01 ET | 2063 | 43.55 |
10:06 ET | 2736 | 43.255 |
10:08 ET | 3901 | 43.05 |
10:10 ET | 3932 | 43.235 |
10:12 ET | 4423 | 43.495 |
10:14 ET | 726 | 43.2813 |
10:15 ET | 300 | 43.505 |
10:19 ET | 1219 | 43.45 |
10:21 ET | 300 | 43.505 |
10:24 ET | 100 | 43.58 |
10:26 ET | 1537 | 43.48 |
10:28 ET | 1860 | 43.49 |
10:30 ET | 2745 | 43.25 |
10:32 ET | 934 | 43.289 |
10:33 ET | 369 | 43.2 |
10:35 ET | 13714 | 43.665 |
10:37 ET | 884 | 43.53 |
10:39 ET | 900 | 43.55 |
10:42 ET | 300 | 43.5 |
10:44 ET | 400 | 43.46 |
10:46 ET | 2349 | 43.365 |
10:48 ET | 3776 | 43.3725 |
10:50 ET | 500 | 43.4 |
10:51 ET | 2675 | 43.33 |
10:53 ET | 2165 | 43.315 |
10:55 ET | 400 | 43.38 |
10:57 ET | 400 | 43.475 |
11:00 ET | 1158 | 43.44 |
11:02 ET | 400 | 43.45 |
11:04 ET | 1800 | 43.28 |
11:06 ET | 1441 | 43.27 |
11:08 ET | 920 | 43.17 |
11:09 ET | 400 | 43.1 |
11:11 ET | 1300 | 43.13 |
11:13 ET | 1500 | 43.07 |
11:15 ET | 950 | 43.1 |
11:18 ET | 1605 | 43.13 |
11:20 ET | 1400 | 43.04 |
11:22 ET | 1749 | 43 |
11:24 ET | 1046 | 42.935 |
11:26 ET | 1954 | 42.91 |
11:27 ET | 1361 | 42.97 |
11:29 ET | 500 | 42.91 |
11:31 ET | 2566 | 42.85 |
11:33 ET | 1200 | 42.81 |
11:36 ET | 1996 | 42.85 |
11:38 ET | 917 | 42.87 |
11:40 ET | 600 | 42.91 |
11:42 ET | 1630 | 42.94 |
11:44 ET | 1040 | 42.97 |
11:45 ET | 200 | 42.97 |
11:47 ET | 300 | 43.02 |
11:49 ET | 200 | 43.08 |
11:54 ET | 400 | 43.07 |
11:56 ET | 2436 | 42.9407 |
11:58 ET | 1826 | 43.04 |
12:00 ET | 883 | 42.92 |
12:02 ET | 9968 | 43.21 |
12:03 ET | 1003 | 43.4 |
12:05 ET | 2052 | 43.32 |
12:07 ET | 1440 | 43.29 |
12:09 ET | 1400 | 43.22 |
12:12 ET | 1953 | 43.26 |
12:14 ET | 100 | 43.24 |
12:18 ET | 403 | 43.3 |
12:20 ET | 400 | 43.28 |
12:21 ET | 100 | 43.26 |
12:23 ET | 1200 | 43.265 |
12:25 ET | 3923 | 43.29 |
12:27 ET | 1000 | 43.32 |
12:30 ET | 3352 | 43.19 |
12:32 ET | 1696 | 43.2 |
12:34 ET | 800 | 43.17 |
12:36 ET | 300 | 43.1975 |
12:38 ET | 6405 | 43.01 |
12:39 ET | 600 | 42.95 |
12:41 ET | 400 | 42.96 |
12:43 ET | 200 | 42.94 |
12:45 ET | 3989 | 42.84 |
12:48 ET | 400 | 42.79 |
12:50 ET | 1800 | 43 |
12:52 ET | 2020 | 42.94 |
12:54 ET | 400 | 42.945 |
12:56 ET | 2400 | 42.85 |
12:57 ET | 500 | 42.855 |
12:59 ET | 1323 | 42.89 |
01:06 ET | 1765 | 42.93 |
01:08 ET | 505 | 42.9 |
01:10 ET | 500 | 42.86 |
01:12 ET | 2273 | 42.68 |
01:14 ET | 600 | 42.71 |
01:15 ET | 500 | 42.72 |
01:17 ET | 336 | 42.725 |
01:19 ET | 100 | 42.725 |
01:21 ET | 4692 | 42.9 |
01:24 ET | 27903 | 42.97 |
01:26 ET | 600 | 42.91 |
01:28 ET | 200 | 42.85 |
01:32 ET | 290 | 42.935 |
01:33 ET | 4648 | 42.75 |
01:35 ET | 11798 | 42.785 |
01:37 ET | 2562 | 42.76 |
01:39 ET | 600 | 42.77 |
01:42 ET | 300 | 42.72 |
01:44 ET | 1151 | 42.805 |
01:48 ET | 7777 | 42.61 |
01:50 ET | 2827 | 42.55 |
01:51 ET | 550 | 42.56 |
01:53 ET | 3034 | 42.45 |
01:55 ET | 700 | 42.46 |
01:57 ET | 2125 | 42.42 |
02:00 ET | 3516 | 42.415 |
02:02 ET | 3230 | 42.45 |
02:04 ET | 1464 | 42.465 |
02:06 ET | 1100 | 42.415 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Agios Pharmaceuticals Inc | 2.5B | -6.7x | --- |
Intellia Therapeutics Inc | 2.4B | -4.7x | --- |
Apogee Therapeutics Inc | 2.4B | -19.5x | --- |
MoonLake Immunotherapeutics | 2.6B | -54.1x | --- |
Celldex Therapeutics Inc | 2.3B | -12.4x | --- |
CG Oncology Inc | 2.3B | -29.4x | --- |
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.5B |
---|---|
Revenue (TTM) | $29.4M |
Shares Outstanding | 56.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.78 |
EPS | $-6.31 |
Book Value | $14.50 |
P/E Ratio | -6.7x |
Price/Sales (TTM) | 85.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,336.42% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.